Catalog No.
Product Name
Application
Product Information
Citations
-
topoisomerase IV inhibitor
Ciprofloxacin hydrochloride is a broad-spectrum antimicrobial carboxyfluoroquinoline, an fluoroquinolone antibiotic that is widely used as an antimicrobial and immunomodulatory agent -
topoisomerase II inhibitor
Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor. - Phenoxodiol, a synthetic analog of Genestein, activates the mitochondrial caspase system, inhibits XIAP (an apoptosis inhibitor), and sensitizes the cancer cells to Fas-mediated apoptosis.
-
topoisomerase I inhibitor
Karenitecin (Cositecan) is a topoisomerase I inhibitor, with potent anti-cancer activity. -
Topoisomerase I inhibitor
Edotecarin is a potent inhibitor of topoisomerase I that can induces single-strand DNA cleavage, with IC50 of 50 nM. - Banoxantrone dihydrochloride is a novel bioreductive agent that can be reduced to a stable, DNA-affinic compound AQ4, which is a potent topoisomerase II inhibitor.
- Banoxantrone D12 dihydrochloride (AQ4N D12 dihydrochloride) is the deuterium labeled banoxantrone dihydrochloride. Banoxantrone is a novel bioreductive agent that can be reduced to a stable, DNA-affinic compound AQ4, which is a potent topoisomerase II inhibitor.
- Banoxantrone D12 (AQ4N D12) is the deuterium labeled banoxantrone. Banoxantrone is a novel bioreductive agent that can be reduced to a stable, DNA-affinic compound AQ4, which is a potent topoisomerase II inhibitor.
-
gyrase B inhibitor
VXc-486 is a gyrase B inhibitor, with bactericidal activity. -
DNA topoisomerase I/II inhibitor
Intoplicine is a DNA topoisomerase I and II inhibitor. -
antibacterial candidate for clinical trials
Zabofloxacin (DW-224a Free base) is a novel fluoronaphthyridone quinolone with a 7-pyrrolidone substituent that is considered a potent antibacterial candidate for clinical trials. - Bisantrene is a highly effective antitumor drug, targets eukaryotic type II topoisomerases.
- Aldoxorubicin (INNO-206) is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.
-
Topoisomerase inhibitor
Voreloxin Hcl is a small molecule and a naphthyridine analogue with antineoplastic activity; inhibitor of Topo II. -
DNA topoisomerase I inhibitor
Exatecan Mesylate is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and can be used in cancer research. - Gatifloxacin (hydrochloride) is an antibiotic of the fourth-generation fluoroquinolone family, it inhibits the bacterial enzymes DNA gyrase and topoisomerase IV.
- Gatifloxacin (mesylate) is an antibiotic of the fourth-generation fluoroquinolone family, it inhibits the bacterial enzymes DNA gyrase and topoisomerase IV.
-
Topoisomerase inhibitor
Zabofloxacin hydrochloride (DW-224a) is a novel fluoronaphthyridone quinolone that is considered a potent antibacterial candidate for clinical trials. -
topoisomerase II inhibitor
Daunorubicin (Daunomycin; RP 13057; Rubidomycin) is a topoisomerase II inhibitor with potent antineoplastic activities. -
Topoisomerase Inhibitor
Cholesterol hemisuccinate Tris salt is a topoisomerase inhibitor that exhibits hepatoprotective and anticancer properties. This compound effectively mitigates acetaminophen-induced hepatotoxicity and prevents subsequent hepatic apoptosis and necrosis. By inhibiting DNA polymerase and DNA topoisomerase, it disrupts DNA replication and repair processes, ultimately inhibiting cell division and tumor growth. Additionally, this compound is suitable for buffer preparation in various laboratory applications. -
Topoisomerase Inhibitor
Alternariol is a mycotoxin that functions as an inhibitor of topoisomerase I and II. This compound exhibits biological activities such as inducing apoptosis, triggering cell cycle arrest, and suppressing innate immune responses, making it valuable for cancer research. Additionally, Alternariol has shown weak estrogenic and antiandrogen effects, along with genotoxic and mutagenic properties, which are relevant to studies on endocrine disruption and its implications in toxicology. -
DNA Topoisomerase I Inhibitor
Podocarpusflavone A is a selective inhibitor of DNA topoisomerase I, demonstrating notable anti-proliferative effects. It has been shown to induce apoptosis in MCF-7 breast cancer cells, suggesting its potential as an anti-tumor agent. This compound is suitable for research applications focused on cancer biology and the mechanistic exploration of cell growth regulation. -
Topoisomerase I/II Inhibitor
SelB-1 is a dual inhibitor targeting Topoisomerase I and II, demonstrating significant anticancer activity. This compound is particularly useful in the study of prostate and colon cancers. Additionally, SelB-1 induces autophagy gene expression and lipid peroxidation, while effectively lowering glutathione (GSH) levels, providing insights into its mechanistic roles in cancer biology. -
Topoisomerase Inhibitor
Hycanthone is a potent topoisomerase inhibitor that functions as a thioxanthenone DNA intercalator. It effectively inhibits RNA synthesis and the activity of DNA topoisomerases I and II, leading to a reduction in nucleic acid biosynthesis. Additionally, Hycanthone demonstrates significant inhibition of apurinic endonuclease-1 (APE1) through direct protein binding, with a binding affinity (KD) of 10 nM. This compound is recognized as a bioactive metabolite of Lucanthone and is noted for its anti-schistosomal properties, making it valuable in related research applications. -
Topoisomerase Inhibitor
Netropsin dihydrochloride is a potent topoisomerase inhibitor that functions as a minor-groove binder. It effectively inhibits the catalytic activity of isolated topoisomerases, disrupting the stabilization of cleavable complexes associated with topoisomerase I and II in the nucleus. Additionally, netropsin dihydrochloride exhibits notable antibacterial and antiviral properties, making it valuable for various research applications, including studies on DNA topology and therapeutic interventions against microbial infections. -
Topoisomerase II Inhibitor
F-14512 is a topoisomerase II inhibitor that selectively targets cancer cells via the polyamine transport system. By enhancing the interaction of polyamines with DNA, F-14512 effectively inhibits topoisomerase II, leading to significant DNA damage and subsequent cellular cytotoxicity, particularly in cells exhibiting high PTS activity. This compound has demonstrated potent antitumor efficacy in the MX1 breast tumor xenograft model, making it a valuable tool for researching breast cancer and exploring mechanisms of drug resistance in oncological studies. -
Topoisomerase I Inhibitor
Irinotecan-d10 is a deuterated derivative of Irinotecan, a potent inhibitor of topoisomerase I. By binding to the topoisomerase I-DNA complex, it disrupts the religation of DNA strands, thereby inducing DNA damage and apoptosis in rapidly dividing cells. This reagent is useful in cancer research, particularly in studies aimed at understanding the mechanisms of action of topoisomerase inhibitors and their therapeutic potential in oncology. -
Topoisomerase Inhibitor
Amonafide L-malate is a topoisomerase II inhibitor that functions as a DNA intercalator. This compound induces apoptotic signaling by disrupting the interaction between topoisomerase II and DNA, leading to inhibited DNA replication and cell proliferation. Amonafide L-malate is utilized in cancer research to study mechanisms of apoptosis and the effects of topoisomerase inhibition on tumor cells. -
Topoisomerase/HDAC Inhibitor
Top/HDAC-IN-1 is a dual inhibitor targeting both topoisomerase and histone deacetylases (HDACs), demonstrating IC50 values of 18 nM for HDAC1, 230 nM for HDAC2, 790 nM for HDAC3, 87 nM for HDAC6, and 5250 nM for HDAC8. This compound exhibits significant antitumor activity against HCT116 cells, with an IC50 of 180 nM, effectively inducing apoptosis and promoting G2 cell cycle arrest. Top/HDAC-IN-1 serves as a valuable tool in cancer research, particularly for studies involving epigenetic modulation and cell proliferation. -
Topoisomerase II Inhibitor
Topoisomerase II inhibitor 7 is a selective inhibitor of the topoisomerase II alpha subtype, demonstrating an IC50 of 3.19 μM. This compound is capable of inducing cell cycle arrest and apoptosis, making it a valuable tool for research into cancer biology and therapeutic strategies. Its inhibition of topoisomerase II has potential applications in exploring mechanisms of genomic stability and drug resistance in cancer cells. -
Topoisomerase I Inhibitor
Topoisomerase I inhibitor 3 is a potent inhibitor that targets topoisomerase I, interfering with the topoisomerase I-DNA complex. This compound demonstrates significant biological activity by inducing apoptosis in HepG2 cancer cells and causing cell cycle arrest at the G2/M phase. It serves as a valuable tool for research applications related to cancer biology and therapeutic development. -
Topoisomerase I/III Inhibitor
Topoisomerase I/II inhibitor 3 is a dual inhibitor targeting both topoisomerase I and II. This compound exhibits potent anti-proliferative effects, inhibiting cell proliferation, invasion, and migration, while also inducing apoptosis through the PI3K/Akt/mTOR signaling pathway. It is particularly relevant for research applications in liver cancer studies. -
Topoisomerase Inhibitor
Topoisomerase Inhibitor 4 is a potent inhibitor targeting topoisomerase I and II. This compound effectively induces cell cycle arrest in the G2/M phase, leading to apoptosis in various cancer cell lines. Its significant antitumor activity makes it a valuable reagent for cancer research applications focused on exploring mechanisms of cell cycle regulation and apoptosis. -
Topoisomerase II Inhibitor
Topoisomerase IIα-IN-5 is an inhibitor of topoisomerase IIα, effectively interfering with its catalytic activity. It operates by intercalating into DNA and binding to the minor groove, thereby inhibiting the enzyme's function. This compound demonstrates enhanced efficacy and reduced genotoxicity compared to Etoposide, making it a valuable tool for research applications focused on cancer therapy and DNA topology modulation. -
Topoisomerase/HDAC Inhibitor
Top/HDAC-IN-3 is an orally active dual inhibitor targeting topoisomerase and histone deacetylase (HDAC). This compound enhances intracellular levels of reactive oxygen species (ROS), leading to DNA damage and subsequently inhibiting cancer cell colony formation and migration. Additionally, Top/HDAC-IN-3 induces apoptosis and cell cycle arrest in cancer cells. In non-small cell lung cancer (NSCLC) models, it demonstrates significant antitumor activity, achieving a tumor growth inhibition (TGI) of 77.5% at a dosage of 100 mg/kg. -
Topoisomerase I/II Inhibitor
Topoisomerase I/II Inhibitor 4 is a potent dual inhibitor targeting both topoisomerase I and II. This compound exhibits significant anti-proliferative effects, inhibiting cell growth, invasion, and migration while promoting apoptosis in cancer cells. Its primary research applications include studies focused on liver cancer therapeutics and the exploration of topoisomerase-related mechanisms in cellular processes. -
HDAC/ Topo II α Inhibitor
KT32 is a potent dual inhibitor targeting histone deacetylases (HDAC) and topoisomerase II alpha (Topo II α). This compound promotes cell death through the activation of apoptotic pathways, making it valuable for research in cancer biology and therapeutic studies. KT32's ability to modulate chromatin structure and DNA topology renders it an essential tool for exploring the mechanisms of tumor progression and treatment resistance. -
Topoisomerase II Inhibitor
Topoisomerase II Inhibitor 15 is a selective inhibitor of topoisomerase II, an enzyme critical for DNA replication and repair. This compound induces apoptosis and exhibits potent activity against head and neck tumors, making it a valuable tool for cancer research. Its mechanism of action further highlights its potential in studying the roles of topoisomerases in tumor biology and therapeutics. -
Topoisomerase II Inhibitor
ICRF-196 is a racemic mixture of the (S,S)- and (R,R)-isomers of ICRF-193, functioning as a potent inhibitor of DNA Topoisomerase II. This compound effectively inhibits DNA synthesis and promotes apoptosis, exhibiting significant anti-cancer and anti-inflammatory properties. Additionally, ICRF-196 demonstrates cardioprotective effects against anthracycline-induced toxicity in cardiomyocytes. It is applicable in research focusing on cancer, infectious diseases, inflammation, and cardiovascular disorders, including acute promyelocytic leukemia. -
Topoisomerase IV Inhibitor
Ciprofloxacin lactate functions as a potent inhibitor of topoisomerase IV. It is known to induce damage to both mitochondrial and nuclear DNA, resulting in mitochondrial dysfunction and increased reactive oxygen species (ROS) production. Additionally, ciprofloxacin lactate displays significant anti-proliferative properties and promotes apoptosis, making it valuable for various research applications in microbiology and cancer studies. This fluoroquinolone antibiotic also demonstrates strong antibacterial activity, contributing to its utility in infectious disease research. -
Topo II/ HDAC Inhibitor
Topo II/HDAC-IN-1 is a potent dual inhibitor targeting Topoisomerase II (Topo II) and histone deacetylases (HDACs). This compound is known to induce apoptosis in cancer cells, making it a valuable tool for research in cancer biology and therapeutic development. Its ability to simultaneously inhibit these targets can provide insights into novel cancer treatment strategies. -
Topoisomerase Inhibitor
Topoisomerase I inhibitor 5 is a potent inhibitor that targets topoisomerase I, exhibiting an IC50 value indicative of its efficacy. This compound disrupts DNA processing and significantly inhibits topoisomerase I activity, leading to cell cycle arrest at the G1 phase and inducing apoptosis in MCF-7 cells. Additionally, Topoisomerase I inhibitor 5 demonstrates potential in reversing P-glycoprotein-mediated resistance to Adriamycin, making it a valuable tool for cancer research.
